(Hypertension. 2001;37:1382.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Correspondence to Kiyoshi Matsumura, MD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail matsumk{at}intmed2.med.kyushu-u.ac.jp
AbstractWe determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0±0.7 mm Hg and 55.4±14.9%, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0±12.8 versus 167.5±42.5 pg/mL, P<0.01; for glucose, 6.66±0.18 versus 7.75±0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.
Key Words: catecholamines central nervous system glucose peptides renal nerves
This article has been cited by other articles:
![]() |
R.H. Hou, R.W. Langley, E. Szabadi, and C.M. Bradshaw Comparison of diphenhydramine and modafinil on arousal and autonomic functions in healthy volunteers J Psychopharmacol, August 1, 2007; 21(6): 567 - 578. [Abstract] [PDF] |
||||
![]() |
R. Spinazzi, P. G. Andreis, G. P. Rossi, and G. G. Nussdorfer Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol. Rev., March 1, 2006; 58(1): 46 - 57. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Dergacheva, X. Wang, Z.-G. Huang, E. Bouairi, C. Stephens, C. Gorini, and D. Mendelowitz Hypocretin-1 (Orexin-A) Facilitates Inhibitory and Diminishes Excitatory Synaptic Pathways to Cardiac Vagal Neurons in the Nucleus Ambiguus J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1322 - 1327. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Young, M. Wu, K. F. Manaye, P. Kc, J. S. Allard, S. O. Mack, and M. A. Haxhiu Orexin stimulates breathing via medullary and spinal pathways J Appl Physiol, April 1, 2005; 98(4): 1387 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yasuda, A. Takeda, S. Fukuda, H. Suzuki, M. Ishimoto, Y. Mori, H. Eguchi, R. Saitoh, H. Fujihara, K. Honda, et al. Orexin A Elicits Arousal Electroencephalography Without Sympathetic Cardiovascular Activation in Isoflurane-Anesthetized Rats Anesth. Analg., December 1, 2003; 97(6): 1663 - 1666. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ciriello and C. V. R. de Oliveira Cardiac effects of hypocretin-1 in nucleus ambiguus Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1611 - R1620. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. R. de Oliveira, M. P. Rosas-Arellano, L. P. Solano-Flores, and J. Ciriello Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1369 - H1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shirasaka, M. Takasaki, and H. Kannan Cardiovascular effects of leptin and orexins Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R639 - R651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Kukkonen, T. Holmqvist, S. Ammoun, and K. E. O. Akerman Functions of the orexinergic/hypocretinergic system Am J Physiol Cell Physiol, December 1, 2002; 283(6): C1567 - C1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsumura, T. Tsuchihashi, K. Fujii, I. Abe, and M. Iida Central Ghrelin Modulates Sympathetic Activity in Conscious Rabbits Hypertension, November 1, 2002; 40(5): 694 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsumura, T. Tsuchihashi, and I. Abe Central Human Cocaine- and Amphetamine-Regulated Transcript Peptide 55-102 Increases Arterial Pressure in Conscious Rabbits Hypertension, November 1, 2001; 38(5): 1096 - 1100. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |